L'Oreal S.A. header image

L'Oreal S.A.

OR

Equity

ISIN FR0000120321 / Valor 502805

Euronext - Euronext Paris (2026-04-30)
EUR 366.05+0.12%

L'Oreal S.A.
UMushroom community rating:

star star star star star
4.33 3 votes No rating yet
NegativeNeutralPositive

About company

L'Oréal S.A. is a French multinational cosmetics and personal-care company that develops, manufactures and markets a broad portfolio of brands across haircare, skincare, makeup, hair colour and fragrances, serving mass-market, premium and professional segments. Organized into business divisions such as Consumer Products, L'Oréal Luxe, Professional Products and Active Cosmetics, the company distributes through supermarkets and drugstores, department stores, salons, pharmacies and an expanding e-commerce channel, and maintains a global network of research and development centers to support product innovation and brand differentiation. Publicly traded on Euronext Paris and a major component of France’s benchmark indices, L'Oréal combines brand management, marketing, supply-chain scale and targeted acquisitions to compete across geographic markets and price tiers.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-5.41%1Y
-15.4%3Y
7.14%5Y

Performance

25.9%1Y
23.4%3Y
24.3%5Y

Volatility

Market cap

229615 M

Market cap (USD)

Daily traded volume (Shares)

467,263

Daily traded volume (Shares)

1 day high/low

343.5 / 337.1

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.33

3 votes
Performance:
starstarstarstarstar
4.33
Innovation:
starstarstarstarstar
4.33
Society:
starstarstarstarstar
4.67
Nature:
starstarstarstarstar
3.67
Marie-Laetitia LEYNEN
Spain, 09 Dec 2025
star star star star star
The company shows resilient performance, deep societal impact, and long-term growth potential, making it a high-quality equity for a balanced macro-focused investor.
Nargita Apte
United Kingdom, 20 Oct 2025
star star star star star
Recent Press Release - they are acquiring Kering's beauty portfolio so likely to rise
Federico Ferrari
Switzerland, 19 Oct 2025
star star star star star
L’Oréal is a strong stock to invest in. In 2023, it reported over €38 billion in revenue. The company operates in more than 150 countries. It consistently pays dividends to investors. Stable and solid, it inspires trust on the stock market.

EQUITIES OF THE SAME SECTOR

Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc Amphastar Pharmaceuticals Inc Valor: 24511852
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.36%USD 21.88
Schrodinger Inc
Schrodinger Inc Schrodinger Inc Valor: 51947209
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.60%USD 12.39
International Flavors & Fragrances Inc
International Flavors & Fragrances Inc International Flavors & Fragrances Inc Valor: 941876
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.87%USD 70.81
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.35%USD 2.84
Outset Medical Inc
Outset Medical Inc Outset Medical Inc Valor: 56717137
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.11%USD 4.36
BridgeBio Pharma Inc
BridgeBio Pharma Inc BridgeBio Pharma Inc Valor: 48204826
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.59%USD 68.56
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc Protagonist Therapeutics Inc Valor: 33278818
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.61%USD 98.37
Allogene Therapeutics Inc
Allogene Therapeutics Inc Allogene Therapeutics Inc Valor: 43756548
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.94%USD 2.15
Summit Therapeutics Inc
Summit Therapeutics Inc Summit Therapeutics Inc Valor: 56903013
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-24.91%USD 16.11
Glaukos Corp
Glaukos Corp Glaukos Corp Valor: 28262610
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.40%USD 140.22